论文信息 - Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes - 字舞流文

Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes

M. Knip | D. Dunger | M. Marcovecchio | T. Tree | M. Haller | S. Bruggraber | A. Schulte | A. Mander | C. Wilhelm-Benartzi | A. Chhabra | Sarah E Miller | S. Bond | C. Mathieu | P. Chmura | A. Nitsche | Bärbel Aschemeier-Fuchs | Mark Wilson | L. Overbergh | Diane Picton | Katrina Gatley | A. E. J. Hendriks | Hilde Morobé | Jaivier Pall | Olivier Arnaud